What is Summit Therapeutics Debt-to-Equity?
Summit Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.81 Mil. Summit Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $103.29 Mil. Summit Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $77.69 Mil.
Summit Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 1.37.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Summit Therapeutics's Debt-to-Equity or its related term are showing as below:
SMMT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.41 Med: 0.03 Max: 4.1
Current: 1.37
During the past 13 years, the highest Debt-to-Equity Ratio of Summit Therapeutics was 4.10. The lowest was -0.41. And the median was 0.03.
Summit Therapeutics Debt-to-Equity Historical Data
The historical data trend for Summit Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Summit Therapeutics Debt-to-Equity Chart
|
Summit Therapeutics Annual Data
|
|
Trend |
Jan14 |
Jan15 |
Jan16 |
Jan17 |
Jan18 |
Jan19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.02 |
0.01 |
0.03 |
4.10 |
1.37 |
|
Summit Therapeutics Quarterly Data
|
|
Jan19 |
Apr19 |
Jul19 |
Oct19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
4.10 |
0.78 |
0.90 |
1.07 |
1.37 |
Competitive Comparison of Summit Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Summit Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Summit Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Summit Therapeutics's Debt-to-Equity falls into.
Summit Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Summit Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Summit Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Summit Therapeutics (Summit Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
| Ankur Dhingra |
officer: Chief Financial Officer |
C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Maky Zanganeh |
director |
51 ADAM WAY, ATHERTON CA 94027 |
| Manmeet Singh Soni |
director |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
| Robert W Duggan |
director, 10 percent owner, officer: See Remarks |
611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756 |
| Yu Xia |
director |
6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437 |
| Robert F. Booth |
director |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
| Alessandra Cesano |
director |
700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065 |
| Urte Gayko |
director |
C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
| Kenneth A Clark |
director |
C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085 |
| Jeffrey R Maranian |
officer: VP, Corporate Controller |
C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Luhua Wang |
director |
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| David Jonathan Powell |
officer: Chief Scientific Officer |
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Camilla Graham |
officer: Chief Clinical Affairs Officer |
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Ventzislav Stefanov |
director, officer: See Remarks |
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Ujwala Mahatme |
director |
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Summit Therapeutics (Summit Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SMMT has been successfully added to your